The present invention relates to the fields of transgenic plants and control of target gene expression. More specifically, the present invention provides compositions and methods for the production of edible plants expressing RNAi effective to downregulate important therapeutic targets. Such plants, their derivatives, seeds or progeny can be ingested for the prevention and/or treatment of disease or infection.
Several publications and patent documents are cited throughout the specification in order to describe the state of the art to which this invention pertains. Each of these citations is incorporated herein by reference as though set forth in full.
Viruses such as hepatitis C virus (HCV), avian influenza (H5N1) and the human immunodeficiency virus (HIV) pose difficult targets for traditional therapies and preventive measures. Their rapid mutation and recombination rates make monotherapeutics involving single targets ineffective in the long term. Although RNA interference (RNAi) triggered by administration or expression of small double-stranded RNAs (dsRNAs) of 21-25 nucleotides targeting essential components of various viruses has been shown to be effective in suppressing their replication in host cells, spontaneous mutations in the targeted virus can evolve to escape this repression. In addition, the ultimate deployment of RNAi as an antiviral therapeutics in the developing world will likely be hampered by the economics involved. Thus, the process by which such dsRNA molecules can be produced and delivered to people who need them most, such as places that are high risk for AIDS, may be another critical factor. Clearly, compositions and methods which are effective for deployment of RNAi in vivo for a variety of therapeutic applications are urgently needed.
In accordance with the present invention, compositions and methods are provided for the delivery of small RNA molecules in vivo for the treatment of infection or disease. In one embodiment, transgenic plants, e.g., tomato, tobacco, carrot, lettuce, potato, rice, corn, cucumber and zucchini), comprising a nucleic acid construct encoding at least one inhibitory RNA molecule are disclosed. In another embodiment, 2, 3, 4 or 5 inhibitory RNA molecules can be introduced into said plant. Exemplary RNAi for use in the invention include those effective against certain viral pathogens which include, but are not limited to human immunodeficiency virus, hepatitis C virus, influenza virus.
In yet another aspect, a method for inhibiting viral infection or disease in a mammal is disclosed. An exemplary method entails ingestion of an effective amount of the transgenic plant or fruit of the invention by said mammal, said plant or fruit expressing at least one nucleic acid construct encoding an inhibitory RNA, said inhibitory RNA being effective to inhibit viral infection, and/or replication or disease in said mammal
Also encompassed by the present invention are transgenic plants and fruits which express RNAi of interest. Also provided are seeds and progeny of such plants.
Edible plants and plant products engineered to express functional RNAs (i.e. siRNA, miRNA, LncRNA, etc.) should be useful for modulating gene expression in mammals ingesting such products. For example, antiviral small interfering RNAs (siRNAs) have been shown to effect sequence specific cleavage, a phenomenon referred to in the literature as RNA silencing or interference (RNAi). siRNAs can be designed to target critical regions of viral transcripts or the RNAs in animals that produce proteins which are required for disease development such as pathogen susceptibility or cancer. Aside from RNAi, RNA molecules can also be used to trigger other cellular pathways that can have potential health benefits such as cell specific programmed cell death.
In addition to ingestion of edible fruits, other plant organs as well as processed plant products that retain the engineered RNA species should also be effective as an oral delivery vehicle for the RNA therapeutics. This approach can be used to advantage for viral prevention and treatment for Human Immunodeficiency Virus (Jacque et al. 2002), Hepatitis A and C Viruses (Kusov et al. 2006; Pan et al. 2009), Poliovirus (Gitlin et al. 2002) and Influenza Virus (Ge et al. 2003). In addition, other potential therapeutics targets such as mammalian factors involved in cancer metastasis, blood coagulation trigger tissue factors, membrane receptors involved in virus internalization, oncogenes—to name just a few examples—could be candidates for this strategy as treatment and/or prevention of disease as well. Thus, the present data focused on antiviral siRNAs should be viewed as examples of the types of therapeutically beneficial molecules that can be delivered using the compositions and methods of the present invention. The invention is not limited to these embodiments.
Current RNA therapeutics technology, which involves synthetic small RNA molecules, is costly in terms of nucleotide synthesis, storage, shipping and delivery. The common delivery route by injection is also undesirable, especially in cases where regular, repeated application is necessary. The use of edible transgenic plants and plant products as delivery vehicles for RNA therapeutics can provide a low-cost alternative approach that can be incorporated into the diet. This will also avoid the need for repeated injections, which is inconvenient as well as painful, in addition to increasing the chance of spreading of diseases or contracting new infections.
The compositions and methods of the invention are useful for down modulation of RNA targets in mammalian cells. The terms “inhibit,” “inhibition,” “inhibiting”, “reduced”, “reduction” and the like as used herein refer to any decrease in the expression or function of a target gene product, including any relative decrement in expression or function up to and including complete abrogation of expression or function of the target gene product.
The term “expression” as used herein in the context of a gene product refers to the biosynthesis of that gene product, including the transcription and/or translation of the gene product. Inhibition of expression or function of a target gene product (i.e., a gene product of interest) can be in the context of a comparison between any two plants, for example, expression or function of a target gene product in a genetically altered plant versus the expression or function of that target gene product in a corresponding wild-type plant. Alternatively, inhibition of expression or function of the target gene product can be in the context of a comparison between plant cells, organelles, organs, tissues, or plant parts within the same plant or between plants, and includes comparisons between developmental or temporal stages within the same plant or between plants. Any method or composition that down-regulates expression of a target gene product, either at the level of transcription or translation, or down-regulates functional activity of the target gene product can be used to achieve inhibition of expression or function of the target gene product.
The term “inhibitory sequence” encompasses any polynucleotide or polypeptide sequence that is capable of inhibiting the expression of a target gene product, for example, at the level of transcription or translation, or which is capable of inhibiting the function of a target gene product. Exemplary constructs encoding such inhibitory sequences are disclosed herein.
When the phrase “capable of inhibiting” is used in the context of a polynucleotide inhibitory sequence, it is intended to mean that the inhibitory sequence itself exerts the inhibitory effect; or, where the inhibitory sequence encodes an inhibitory nucleotide molecule (for example, hairpin RNA, miRNA, or double-stranded RNA polynucleotides), or encodes an inhibitory polypeptide (i.e., a polypeptide that inhibits expression or function of the target gene product), following its transcription (for example, in the case of an inhibitory sequence encoding a hairpin RNA, miRNA, or double-stranded RNA polynucleotide) or its transcription and translation (in the case of an inhibitory sequence encoding an inhibitory polypeptide), the transcribed or translated product, respectively, exerts the inhibitory effect on the target gene product (i.e., inhibits expression or function of the target gene product).
Conversely, the terms “increase”, “increased, ” and “increasing” in the context of the methods of the present invention refer to any increase in the expression or function of a gene product, including any relative increment in expression or function.
In many instances the nucleotide sequences for use in the methods of the present invention, are provided in transcriptional units with for transcription in the plant of interest. A transcriptional unit is comprised generally of a promoter and a nucleotide sequence operably linked in the 3′ direction of the promoter, optionally with a terminator.
“Operably linked” refers to the functional linkage between a promoter and a second sequence, wherein the promoter sequence initiates and mediates transcription of the DNA sequence corresponding to the second sequence. The expression cassette will include 5′ and 3′ regulatory sequences operably linked to at least one of the sequences of the invention.
Generally, in the context of an over expression cassette, operably linked means that the nucleotide sequences being linked are contiguous and, where necessary to join two or more protein coding regions, contiguous and in the same reading frame. In the case where an expression cassette contains two or more protein coding regions joined in a contiguous manner in the same reading frame, the encoded polypeptide is herein defined as a “heterologous polypeptide” or a “chimeric polypeptide” or a “fusion polypeptide”. The cassette may additionally contain at least one additional coding sequence to be co-transformed into the organism. Alternatively, the additional coding sequence(s) can be provided on multiple expression cassettes.
The methods of transgenic expression can be used to decrease the level of at least one targeted viral sequence, following ingestion of transgenic tomatoes expressing an RNAi specific for the viral transcript. In cases where multiple molecules are required to suppress gene expression or viral replication the transgenic plants or fruits of the invention can comprise 1, 2, 3, 4 or 5 or more different therapeutically beneficial sRNA molecules. The methods of transgenic expression comprise transforming a plant cell with at least one expression cassette comprising a promoter that drives expression in the plant operably linked to at least one nucleotide sequence encoding an RNAi that inhibits production of the desired target protein(s) encoded either by viruses or in the animal. Methods for expressing transgenic genes in plants are well known in the art.
Plant transformants containing a desired genetic modification as a result of any of the above described methods can be selected by various methods known in the art. These methods include, but are not limited to, methods such as SDS-PAGE analysis, immunoblotting using antibodies which bind to the seed protein of interest, single nucleotide polymorphism (SNP) analysis, or assaying for the products of a reporter or marker gene, and the like.
As used herein, the terms “reporter,” “reporter system”, “reporter gene,” or “reporter gene product” shall mean an operative genetic system in which a nucleic acid comprises a gene that encodes a product that when expressed produces a reporter signal that is a readily measurable, e.g., by biological assay, immunoassay, radio immunoassay, or by colorimetric, fluorogenic, chemiluminescent or other methods. GUS is exemplified herein. The nucleic acid may be either RNA or DNA, linear or circular, single or double stranded, and is operatively linked to the necessary control elements for the expression of the reporter gene product. The required control elements will vary according to the nature of the reporter system and whether the reporter gene is in the form of DNA or RNA, but may include, but not be limited to, such elements as promoters, enhancers, translational control sequences, poly A addition signals, transcriptional termination signals and the like.
The materials and methods set forth below are provided to facilitate the practice of the present invention.
To facilitate the construction of double strand RNA (dsRNA)-producing vector for plant transformation, a Gateway Technology-based vector was constructed in the backbone of pBI121 (Lam E, unpublished result) using the recombinase targeting regions derived from the Hellsgate2 vector (Wesley et al. 2001). This binary vector, designated as EL420 (
Cotyledon explants from sterile tomato (cv. Moneymaker) were used for transformation with the HIVi, NPi and HCVi vectors via Agrobacterium as described by McCormick (1991) and tissue culture conditions modified by Ruf et al. (2001). The skilled person is well aware of the variety of different methods currently available to introduce exogenous nucleic acids into plants and plant cells. These include without limitation, electroporation, biolistic delivery of DNA coated particles, protoplast fusion, transfection etc.
The following example is provided to facilitate practice of the present invention. It is not intended to limit the invention in any way.
We have constructed binary vectors using 306 to 500 base pairs (bps) of essential regions from the influenza virus H1N1 (IFV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) to produce dsRNAs from these sequences in transgenic plants. 500 and 498 bps of the nucleoprotein (NP) encoding segments of the H1N1 and HCV were used respectively, while 306 bps of the Tat gene from HIV was used (
We carried out quantitative analysis of GUS expression in these 12 transgenic tomato lines in leaves of mature plants, as well as from green and ripened fruits (
After this series of analyses, we propagated these tomato lines asexually by stem cuttings and transplantation of the new shoots. At the same time, we also worked to detect the production of the target siRNA repertoires for the respective viral sequences in the tomato lines. First, we worked to detect the siRNAs produced in the leaf and fruit tissues of the transgenic plants. We followed published protocols to enrich for sRNAs in our nucleic acid purification method, followed by polyacrylamide gel electrophoresis (PAGE) separation and northern blot analyses.
Surprisingly, similar levels of siRNAs were detected for the 4 NPi lines (data not shown) as in the 4 HCVi lines although two of these lines (7B-1, 7B-8) showed very low GUS expression in ripened fruits (
To quantify the small RNAs such as miRNAs and siRNAs in tomato fruits with high sensitivity and specificity, we adapted the “Key-Like-Primer” (KLP)-TaqMan technology recently published by Yang et al. (Plant Biotech. J. [2009] 7:1-10) for the quantitative and specific detection of siRNAs. This method has been shown to be capable of detecting miRNAs and siRNAs at levels as low as 10 copies per cell. Importantly, this technique is amenable to the use of total RNA and thus obviates the need to use siRNA preparations that are more tedious to prepare. To aid our effort in detecting and quantifying various tomato RNA species in animal tissues and blood after ingestion, we also designed and synthesized TaqMan PCR probes for various nuclear- and plastid-encoded genes of tomato. The data from their use in transcript quantification using tomato fruit RNAs prepared from wild-type (WT) or transgenic lines are shown in
The relative levels of transcript for the five protein- and rRNA-encoding genes are in the order of 16S rRNA>RbcL>ACCS>TomUbi3>RpoC1 (panel A,
In the case of C. elegans, dsRNA are expressed in E. coli bacteria which in turn are used as food for the nematode. The RNAi signal can then persist to the next generation after the initial feeding to silence expression of the targeted gene. The mammalian digestive system is very different from that of nematodes, however the potential benefit from such a simple delivery route for RNAi triggers warrants its examination. To examine the question of whether tomato-derived RNAs can in fact survive the mammalian digestive system and make it to the bloodstream and organs, we have performed feeding studies with rabbits that have been fed a simple tomato diet for a week before blood and tissues are drawn and analyzed for the presence of tomato-specific transcripts. In
Viruses such as hepatitis C virus (HCV), avian influenza (H5N1) and the human immunodeficiency virus (HIV) pose difficult targets for traditional therapies and preventive measures. Their rapid mutation and recombination rates make monotherapeutics involving single targets ineffective in the long term. Although RNA interference (RNAi) triggered by administration or expression of small double-stranded RNAs (dsRNAs) of 21-25 nucleotides targeting essential components of various viruses has been shown to be effective in suppressing their replication in host cells, spontaneous mutations in the targeted virus enable the virus to escape this repression. In addition, the ultimate deployment of RNAi as an antiviral therapeutics in the developing world will likely be hampered by the economics involved.
As demonstrated herein and elsewhere, plant cells tolerate long strand dsRNAs from several hundred up to several thousand bases and thus can produce a large repertoire of siRNAs from a single transcription unit. Previously, we have demonstrated that siRNAs (small interfering RNAs) targeting a 400 nucleotide conserved region of the influenza NS1 protein can be constitutively produced in transgenic tobacco and these plant-derived siRNAs are effective in virus suppression in transfection studies involving mammalian cells (Zhou et al. FEBS Lett., 2004). This strategy can be easily scaled up to express several kilobases (kbs) of sequences that would contain multiple viral genome targets for combinatorial silencing. Thus plants are excellent natural “factories” to produce complex RNAi triggers economically on an agricultural scale.
In additional experiments, we demonstrate that tomato-expressed siRNAs down modulate the appropriate viral sequences in mammalian cells. In addition to detecting the production of siRNA repertoires against IFV (NPi), HCV (HCVi) and HIV (HIVi) in tomato fruits, we wanted to verify and quantify the efficacy of these plant-derived siRNAs in eliciting the suppression of the respective viral sequences. Such RNAi effects can be readily assayed in animal cell culture using a convenient assay that employs the psiCHECK-2™ vector system (Promega Co., WI). By using a dual luciferase expression cassette that allows the simultaneous quantification of the test gene vs. a common reference gene, this system enables facile normalization of the gene suppression that may result from RNAi suppression via an inserted sequence. Three different psiCHECK-2 derived constructs (pRD43, pRD51 and pRD52) with the viral sequences that were used to construct the binary vectors shown in
These data demonstrate the high degree of specificity and efficacy of the three sets of siRNAs that our transgenic fruits produced. The degree of specific gene suppression observed in our assay is especially impressive since previous work with synthetic siRNA or shRNA designed for a specific site on target genes are usually not very effective, with an average of only 1 in 5 of the sites selected showing efficient gene silencing of 80% or more (Kapadia et al. [2003] PNAS 100: 2014-8; Hohjoh [2002] FEBS Lett. 521: 195-9). This can be explained by the fact that in generating a collection of ˜21 nt siRNAs from our viral sequences, our plant expression system likely produces a repertoire of 15 to 25 distinct siRNA species from each of our transgenes in the different tomato lines. The increase in potential target site numbers for the transcript in question thus can contribute to the more robust suppression observed. Our observations demonstrated that fruit-derived siRNA repertoires could direct efficient and specific RNAi against transcripts encoding critical components of animal viral pathogens.
Lastly, we also tested the generality of this uptake phenomenon by examining the ability of plant miRNA and transgenically-produced siRNAs to be taken up in mice via the GI tract.
In a recent study, mature plant miRNA has been reported to be especially stable in the GI tract of mammals, likely due to the specific methylation that is found in sRNAs of plants but not usually found in animal sRNAs (Zhang et al. 2012). Plant siRNAs are also methylated in a similar fashion and thus are expected to be similarly protected. In the data reported, the rice miRNA168a was found to be incorporated into the mouse RISC complex (based on immunoprecipitation studies with anti-AGO2 antiserum) after uptake in mice and was functional to suppress its target in the animal's cells via translational inhibition. This crucial data provides support for the expectation that the plant-derived sRNAs will be functional after their uptake into the animal's system. Finally, the rice miRNAs under investigation were found to be accessible to various mice tissues, as we have shown for rabbits.
While the invention has been described in detail and with reference to specific examples thereof, it will be apparent to one skilled in the art that various changes and modifications can be made therein without departing from the spirit and scope thereof.
This application claims priority to U.S. Provisional Application 61/470,717 filed Apr. 1, 2011, the entire contents being incorporated herein by reference as though sent forth in full.
Filing Document | Filing Date | Country | Kind | 371c Date |
---|---|---|---|---|
PCT/US12/31830 | 4/2/2012 | WO | 00 | 1/30/2014 |
Number | Date | Country | |
---|---|---|---|
61470717 | Apr 2011 | US |